Prospect: A randomized double-blind phase 3 efficacy study of PROSTVAC-VF immunotherapy in men with asymptomatic/minimally symptomatic metastatic castration-resistant prostate cancer.
2015 ◽
Vol 33
(15_suppl)
◽
pp. TPS5081-TPS5081
◽
Keyword(s):
Phase 3
◽